Please login to the form below

Not currently logged in
Email:
Password:

fitusiran

This page shows the latest fitusiran news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk hits pause on rival to Hemlibra for haemophilia

Novo Nordisk hits pause on rival to Hemlibra for haemophilia

Meanwhile, another non-clotting factor drug for haemophilia  – Alnylam and Sanofi’s RNA interference candidate fitusiran – is also in late-stage development for haemophilia A and B.

Latest news

  • Sanofi narrows focus, shedding diabetes and cardiovascular research Sanofi narrows focus, shedding diabetes and cardiovascular research

    This includes a host of investigational therapies for rare disease and cancers, such as Fitusiran (an RNAi therapeutic for haemophilia A and B), BIVV001 (a factor VIII therapy for haemophilia A)

  • Roche’s Hemlibra scores broader NHS funding Roche’s Hemlibra scores broader NHS funding

    Competition is heating up in haemophilia, however. Alnylam's late-stage candidate fitusiran is tipped as a major competitor to Hemlibra, while the first gene therapies are also on the horizon.

  • ACPs to lead gene therapies in haemophilia market growth ACPs to lead gene therapies in haemophilia market growth

    New therapies to hit existing players. Roche’s Hemlibra and Alnylam’s late-stage candidate fitusiran are likely to seize a bigger share of an expanded haemophilia market than gene therapies, ... The two drugs have distinct mechanisms –  Hemlibra

  • Sanofi exits R&D pact with Alnylam on rare disease Sanofi exits R&D pact with Alnylam on rare disease

    The R&D deal was tweaked in January last year, with Sanofi licensing an RNAi drug called fitusiran for haemophilia A and B as well as other rare bleeding disorders, but ... Prospects for haemophilia candidate fitusiran looked a little shaky in 2017 when

  • FDA lifts clinical hold on Sanofi’s haemophilia drug FDA lifts clinical hold on Sanofi’s haemophilia drug

    Fitusiran holds the potential to help improve the lives of people living with haemophilia,” said Akin Akinc, who is leading the development of the drug at Alnylam. ... With the additional risk mitigation measures in place, we look forward to the

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics